Barclays PLC Reduces Holdings in 2seventy bio, Inc. (NASDAQ:TSVT)

Barclays PLC reduced its stake in 2seventy bio, Inc. (NASDAQ:TSVT) by 62.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 80,594 shares of the company’s stock after selling 132,019 shares during the quarter. Barclays PLC owned about 0.16% of 2seventy bio worth $380,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. SkyView Investment Advisors LLC raised its holdings in shares of 2seventy bio by 25.0% in the second quarter. SkyView Investment Advisors LLC now owns 12,500 shares of the company’s stock worth $48,000 after buying an additional 2,500 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in 2seventy bio during the 3rd quarter worth about $25,000. XTX Topco Ltd grew its stake in 2seventy bio by 61.1% during the 3rd quarter. XTX Topco Ltd now owns 24,416 shares of the company’s stock valued at $115,000 after purchasing an additional 9,257 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of 2seventy bio by 5.4% in the second quarter. Bank of New York Mellon Corp now owns 196,959 shares of the company’s stock valued at $758,000 after purchasing an additional 10,077 shares during the period. Finally, Readystate Asset Management LP purchased a new position in shares of 2seventy bio in the third quarter worth about $53,000. Hedge funds and other institutional investors own 93.90% of the company’s stock.

2seventy bio Stock Up 7.0 %

Shares of NASDAQ TSVT opened at $2.61 on Friday. 2seventy bio, Inc. has a 52 week low of $2.35 and a 52 week high of $6.40. The firm has a market cap of $134.64 million, a P/E ratio of -1.40 and a beta of 1.76. The business’s 50 day moving average price is $3.28 and its 200 day moving average price is $4.15.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.